Metformin use and the risk of bacterial pneumonia in patients with type 2 diabetes.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
28 02 2022
28 02 2022
Historique:
received:
18
10
2021
accepted:
14
02
2022
entrez:
1
3
2022
pubmed:
2
3
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Persons with type 2 diabetes (T2D) have neutrophil dysfunction with a higher risk of infection than those without diabetes. We conducted this study aiming to compare the risk of pneumonia between metformin use and nonuse in persons with T2D. We identified 49,012 propensity score-matched metformin users and nonusers from Taiwan's National Health Insurance Research Database between January 1, 2000, and December 31, 2017. We used the Cox proportional hazards model to compare the risks of pneumonia and respiratory death. The mean (SD) age of the participants was 57.46 (12.88) years, and the mean follow-up time for metformin users and nonusers was 5.47 (3.71) years and 5.15 (3.87) years, respectively. Compared with the nonuse of metformin, the adjusted hazard ratios (95% CI) for metformin use in bacterial pneumonia, invasive mechanical ventilation, and respiratory cause of death were 0.89 (0.84-0.94), 0.77 (0.73-0.82), and 0.64 (0.56-0.74), respectively. A longer cumulative duration of metformin use had further lower adjusted hazard ratios in these risks compared with nonuse. In patients with T2D, metformin use was associated with significantly lower risks of bacterial pneumonia, invasive mechanical ventilation, and respiratory cause of death; moreover, longer metformin use duration was associated with lower hazard ratios of these risks.
Identifiants
pubmed: 35228620
doi: 10.1038/s41598-022-07294-1
pii: 10.1038/s41598-022-07294-1
pmc: PMC8885662
doi:
Substances chimiques
Hypoglycemic Agents
0
Metformin
9100L32L2N
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3270Informations de copyright
© 2022. The Author(s).
Références
Diabetes Care. 2021 Jan;44(Suppl 1):S40-S52
pubmed: 33298415
Lancet Diabetes Endocrinol. 2016 Feb;4(2):148-58
pubmed: 26656292
N Engl J Med. 2011 Mar 03;364(9):829-841
pubmed: 21366474
Diabetes Metab Res Rev. 2007 Jan;23(1):3-13
pubmed: 16960917
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
BMJ Open. 2016 Aug 19;6(8):e011523
pubmed: 27543589
J Formos Med Assoc. 2019 Nov;118 Suppl 2:S83-S89
pubmed: 31351690
Pharmacol Res. 2017 Mar;117:103-128
pubmed: 27939359
Health Aff (Millwood). 2003 May-Jun;22(3):61-76
pubmed: 12757273
Am J Respir Crit Care Med. 2008 Jul 15;178(2):168-79
pubmed: 18436790
Am J Manag Care. 2008 Jan;14(1):15-23
pubmed: 18197741
Lancet Healthy Longev. 2021 Jan;2(1):e34-e41
pubmed: 33521772
J Formos Med Assoc. 2005 Mar;104(3):157-63
pubmed: 15818428
CMAJ. 2014 Apr 1;186(6):415-21
pubmed: 24591276
J Gen Intern Med. 2007 Dec;22 Suppl 3:408-18
pubmed: 18026810
Br J Clin Pharmacol. 2017 Sep;83(9):2034-2044
pubmed: 28294379
PLoS Pathog. 2013;9(12):e1003794
pubmed: 24385898
Respiration. 2015;89(3):253-64
pubmed: 25677307
J Clin Med. 2018 Sep 09;7(9):
pubmed: 30205606
Sci Rep. 2020 Feb 24;10(1):3229
pubmed: 32094377
Diabetologia. 2021 Jan;64(1):109-118
pubmed: 32986145
Diabetologia. 2021 Aug;64(8):1760-1765
pubmed: 33844069
Diabetes Care. 2000 Jan;23(1):95-108
pubmed: 10857977
Thorax. 2013 Sep;68(9):835-45
pubmed: 23709760
Crit Care. 2019 Feb 18;23(1):50
pubmed: 30777119
J Formos Med Assoc. 2019 Nov;118 Suppl 2:S90-S95
pubmed: 31300323